Compare Alibaba Group (BABA) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs Novartis AG — how do they compare? Alibaba Group trades at $118 (market cap $270.70B), while Novartis AG trades at $150.42 (market cap $293.74B). The key difference: Alibaba Group and Novartis AG are close in size by market cap, and Novartis AG pays the higher dividend (3.09%). Which is the better fit depends on your goals.
| BABA | NVS | |
|---|---|---|
Market Cap | $270.70B | $293.74B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $168.62 |
52-Week Low | $94.83 | $113.50 |
Enterprise Value | $265.53B | $333.76B |
Dividend Yield | 0.93% | 3.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $112.35, up 0.02% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings misses contrast with robust fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 17.36 appear reasonable. The stock faces headwinds from securities investigations but benefits from AI-driven optimism in cloud growth.
Outlook remains positive given Wall Street's $195 price target and 86% buy ratings, though risks include legal overhangs and earnings volatility. AI and cloud initiatives offer growth catalysts, but investors should monitor regulatory developments and quarterly execution against expectations.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
